Genentech, a member of the Roche Group announced that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma or BCC, for whom surgery is considered inappropriate.
Pivotal study with vismodegib shows positive results in people with advanced BCC